New Rochelle, NY, November 5, 2012At least 2 million people worldwide will be infected with HIV this year, driving the need for better HIV prevention strategies to slow the global pandemic. A better understanding of how to prevent HIV transmission using antiviral drugs led to approval of the first oral pill for HIV prevention, and microbicides delivered as topical gels or via intravaginal rings are in clinical testing and have yielded both positive and negative results. The complex factors involved in the sexual transmission of HIV, the urgent need for new preventive approaches, and the most promising methods currently in development are examined in a special issue of AIDS Research and Human Retroviruses, a peer-reviewed journal published by Mary Ann Liebert, Inc, publishers. The entire issue is available free on the AIDS Research and Human Retroviruses website at http://www.liebertpub.com/aid.
Guest Editor Patrick Kiser, University of Utah, Salt Lake City, and coauthors Pedro Mesquita and Betsy Herold, Albert Einstein College of Medicine, New York, NY, provide an overview of the scientific and developmental gaps in the field of drug discovery, formulation, and delivery to prevent sexual transmission of HIV. In the article "A Perspective on Progress and Gaps in HIV Prevention Science," they review the prophylactic agents in development and their advantages and limitations, and they present recommendations for future research directions. "The advances we are seeing today are exciting and justify a continued focus on the science and technologies that can make a difference in this public health crisis," says Dr. Kiser.
Peter Anton and coauthors, David Geffen School of Medicine at UCLA and the School of Public Health (Los Angeles, CA), University of Pittsburgh and Medical School (PA), University of North Carolina, Chapel Hill, Johns Hopkins University School of Medicine (B
|Contact: Vicki Cohn|
Mary Ann Liebert, Inc./Genetic Engineering News